US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Instil Bio

News headline image
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
From Instil Bio
Via GlobeNewswire
Tickers ALNY TIL
News headline image
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces Strategic Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
News headline image
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Instil Bio
Via GlobeNewswire
Tickers TIL